卡维地洛对缺血性心脏病患者心肌收缩力的影响

目的研究卡维地洛对缺血性心脏病心肌收缩力及预后的临床疗效。方法选取缺血性心脏病CHF64例，随机分为倍他乐克组（A组，32例）和卡维地洛组（B组，32例），A组和B组在常规药物治疗、病情稳定基础上分别加用倍他乐克和卡维地洛，调整剂量稳定，随访3个月后回医院检测各项指标。结果卡维地洛组和倍他乐克组均能有效降低心率，降低血压，减少左心室LVEDD、LVESD，但前者的LVESD较后者低（P〈0．05），Dd值较后者高（P〈0．05）。倍他乐克组可以明显地减少CO和CI，而卡维地洛组CO和CI变化不明显，两组比较差异有统计学意义（P〈0．05）。两者均可提高每搏输出量和LYEF值，但与治疗后倍他乐克组比较，卡维地洛组有较高的每搏输出量（P〈0．05）和LVEF值（P〈0．01）.结论卡维地洛比倍他乐克的临床疗效好，是一种安全、有效的CHF新药。

Clinnical Effects of Carvedilol on Cardiac Contractility with Ischemic Heart Disease

Objective To explore the effects and safety of Carvedilol on cardiac contractility in ischemic heart disease with the chronic congestive heart failure （ CHF ）. Methods Sixty-four patients with CHF were randomly divided into 2 groups： the Betaloe group （A group,32cases ）and the Carvedilol group （B group,32 cases ）. The A group was treated by Betaloe, while B group by Carvedilol base on the basic treatment. Follow-up for 3 mongths and detect the index. Results Both the two groups could reduce heart rate, blood pressure, left ventricle＇ s LVEDD and LVESD, but the B group had the lower LVESD and higher Dd value than the A group （ P 〈 0.05 ）. CO and CI value of group A was reduced, there was significant difference between two groups （ P 〈 0.05 ）. Group B had the higher SV （ P 〈 0.05 ） and LVEF （ P 〈 0.01 ） than that in group A. Conclusion Carvedilol is more effective than Betaloc. It is a effective and safty treatment to chronic congestive heart failure.